Prostate cancer

GU002

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel

Topic

BR004

Disease

Prostate cancer treatment & diagnosis

Description

Primary Objective: To assess the benefit of docetaxel as measured by improvement in freedom from progression (phase II) and subsequently metastasis free survival (phase III) when given in combination with radiation and androgen deprivation in treatment of high risk prostate cancer post-radical prostatectomy.

Contact

Michigan
Peggy Mouradian

Physicians

John Vito Antonucci

MD

Radiation Oncologist

Madison Heights (Radiation oncology) +3

Alvaro A. Martinez

MD, FACR, FABS, FASTRO

Radiation Oncologist

Pontiac (Radiation oncology) +4

Michael I. Ghilezan

MD, PhD

Radiation Oncologist

Pontiac (Radiation oncology) +3

Frank A. Vicini

MD, FACR, FASTRO, FABS

Radiation Oncologist

Farmington Hills (Radiation oncology) +2